Drug discovery technology 2002. Start-up showcase and structure-based drug design

Effectiveness of lay workers delivering behavioural activation for people with depression: systematic review and meta-analysis.

BJPsych open·2026

Modality-Specific and Multilevel Barriers to Curative Treatment for Early-Stage Hepatocellular Carcinoma.

Liver cancer·2026

Connectivity- vs Scalp-Based Targeting of Accelerated Transcranial Magnetic Stimulation for Depression: A Randomized Clinical Trial.

JAMA psychiatry·2026

Hypertonic saline protects the axo-myelinic interface acutely after contusive SCI and improves postural stability and balance as revealed by motion sequencing (MoSeq).

Experimental neurology·2026

The Reciprocal Insecurity Paradox: A Phenomenological Analysis of the Crisis Encounter Between the Mental Health Nurse and Service User With Complex Emotional Needs.

Nursing inquiry·2026

Modification of early behavioural, physiological and neuropathological endpoints by syntaxin-6 knockout in a humanised P301S transgenic model of tauopathy.

Acta neuropathologica·2026

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010

Total Synthesis of Paliurine E by a Highly Convergent Block Approach.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026

Ring-opening simplification of thiazolyl-pyrazoline-triazole hybrids: synthesis, SAR and antifolate mechanism against Leishmania major.

RSC medicinal chemistry·2026

Metal-drug coordinated nanozymes for ROS scavenging and Kupffer cell polarization to alleviate drug-induced liver injury.

Acta pharmaceutica Sinica. B·2026

Rationale of renewed efforts in developing MC4R modulators to treat metabolic disorders.

Acta pharmaceutica Sinica. B·2026

SASH1 as a Context-Dependent Multi-Docking Scaffold Linking Receptor Signaling to Cytoskeletal Dynamics.

International journal of molecular sciences·2026

Biological Evaluation, Molecular Docking, and in Ovo Hatchability Assessment of Selected Mannich-Type 1,2,4-Triazol-5-one Derivatives.

International journal of molecular sciences·2026

Related Experiment Videos

Drug discovery technology 2002. Start-up showcase and structure-based drug design

Related Concept Videos

Effectiveness of lay workers delivering behavioural activation for people with depression: systematic review and meta-analysis.

Modality-Specific and Multilevel Barriers to Curative Treatment for Early-Stage Hepatocellular Carcinoma.

Connectivity- vs Scalp-Based Targeting of Accelerated Transcranial Magnetic Stimulation for Depression: A Randomized Clinical Trial.

Hypertonic saline protects the axo-myelinic interface acutely after contusive SCI and improves postural stability and balance as revealed by motion sequencing (MoSeq).

The Reciprocal Insecurity Paradox: A Phenomenological Analysis of the Crisis Encounter Between the Mental Health Nurse and Service User With Complex Emotional Needs.

Modification of early behavioural, physiological and neuropathological endpoints by syntaxin-6 knockout in a humanised P301S transgenic model of tauopathy.

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

Total Synthesis of Paliurine E by a Highly Convergent Block Approach.

Ring-opening simplification of thiazolyl-pyrazoline-triazole hybrids: synthesis, SAR and antifolate mechanism against Leishmania major.

Metal-drug coordinated nanozymes for ROS scavenging and Kupffer cell polarization to alleviate drug-induced liver injury.

Rationale of renewed efforts in developing MC4R modulators to treat metabolic disorders.

SASH1 as a Context-Dependent Multi-Docking Scaffold Linking Receptor Signaling to Cytoskeletal Dynamics.

Biological Evaluation, Molecular Docking, and in Ovo Hatchability Assessment of Selected Mannich-Type 1,2,4-Triazol-5-one Derivatives.

Related Experiment Videos

Drug discovery technology 2002. Start-up showcase and structure-based drug design

Related Concept Videos

Related Articles